167 related articles for article (PubMed ID: 21084937)
1. How appropriate are the american college of radiology appropriateness criteria for ovarian cancer screening.
Dubinsky TJ
Ultrasound Q; 2010 Dec; 26(4):225-6. PubMed ID: 21084937
[No Abstract] [Full Text] [Related]
2. Ovarian cancer screening. American College of Radiology. ACR Appropriateness Criteria.
Böhm-Vélez M; Mendelson E; Bree R; Finberg H; Fishman EK; Hricak H; Laing F; Sartoris D; Thurmond A; Goldstein S
Radiology; 2000 Jun; 215 Suppl():861-71. PubMed ID: 11037511
[No Abstract] [Full Text] [Related]
3. ACR appropriateness criteria© ovarian cancer screening.
Brown DL; Andreotti RF; Lee SI; Dejesus Allison SO; Bennett GL; Dubinsky T; Glanc P; Horrow MM; Lev-Toaff AS; Horowitz NS; Podrasky AE; Scoutt LM; Zelop CM
Ultrasound Q; 2010 Dec; 26(4):219-23. PubMed ID: 21084936
[TBL] [Abstract][Full Text] [Related]
4. [Mass-screening for ovarian cancer].
Sato S; Higuchi T; Yokoyama Y; Sakamoto T
Nihon Rinsho; 2004 Oct; 62 Suppl 10():601-4. PubMed ID: 15535316
[No Abstract] [Full Text] [Related]
5. Personalizing ovarian cancer screening.
Goozner M
J Natl Cancer Inst; 2010 Aug; 102(15):1112-3. PubMed ID: 20668268
[No Abstract] [Full Text] [Related]
6. A step forward for two-step screening for ovarian cancer.
Hensley ML
J Clin Oncol; 2010 May; 28(13):2128-30. PubMed ID: 20368556
[No Abstract] [Full Text] [Related]
7. Circulating tumour markers in ovarian tumours.
von Schlippe M; Rustin GJ
Forum (Genova); 2000; 10(4):383-92. PubMed ID: 11535987
[TBL] [Abstract][Full Text] [Related]
8. CA-125: a biomarker put to the test.
Schmidt C
J Natl Cancer Inst; 2011 Sep; 103(17):1290-1. PubMed ID: 21852262
[No Abstract] [Full Text] [Related]
9. [Screening for ovarian cancers: critical analysis].
Pennehouat G; Gugliemina JN; Naouri M; Créquat J; Bouret JM; Thébault Y; Madelenat P
Contracept Fertil Sex; 1993 Mar; 21(3):223-30. PubMed ID: 7951617
[TBL] [Abstract][Full Text] [Related]
10. Screening for ovarian cancer.
Emery J; Yaphe J; Priest P; Whiteman D
Lancet; 1999 Aug; 354(9177):509; author reply 510. PubMed ID: 10465193
[No Abstract] [Full Text] [Related]
11. [The characteristics of CA125/MUC16].
Hiraike O; Yano T; Taketani Y
Nihon Rinsho; 2010 Jul; 68 Suppl 7():681-4. PubMed ID: 20960850
[No Abstract] [Full Text] [Related]
12. Screening for ovarian cancer.
Manassiev N
Lancet; 1999 Aug; 354(9177):509; author reply 510. PubMed ID: 10465192
[No Abstract] [Full Text] [Related]
13. Screening for ovarian cancer.
Chappuis PO; Narod SA; Foulkes WD
Lancet; 1999 Aug; 354(9177):509-10. PubMed ID: 10465194
[No Abstract] [Full Text] [Related]
14. Progress report on ovarian cancer screening. Scientists are making headway in detecting ovarian cancer at an earlier stage.
Harv Womens Health Watch; 2010 Apr; 17(8):1-3. PubMed ID: 20506601
[No Abstract] [Full Text] [Related]
15. Genetic, biochemical, and multimodal approaches to screening for ovarian cancer.
Jacobs I
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S22-7. PubMed ID: 7835805
[No Abstract] [Full Text] [Related]
16. [Serum tumor markers CA125 and HE4 in ovarian cancer patients].
Sergeeva NS; Marshutina NV; Alentov II; Korneeva IA; Novikova EG
Vopr Onkol; 2013; 59(2):12-21. PubMed ID: 23814844
[No Abstract] [Full Text] [Related]
17. [Clinical applications of ovarian cancer biomarkers].
Kataoka F; Aoki D
Nihon Rinsho; 2012 Jun; 70 Suppl 4():543-8. PubMed ID: 23156306
[No Abstract] [Full Text] [Related]
18. [Screening for ovarian cancers: what is the role for marker levels?].
Dargent D
Gynecol Obstet Fertil; 2000 Nov; 28(11):855-9. PubMed ID: 11127045
[No Abstract] [Full Text] [Related]
19. The value of cancer antigen 125 (CA 125) during treatment and follow-up of patients with ovarian cancer.
de Bruijn HW; van der Zee AG; Aalders JG
Curr Opin Obstet Gynecol; 1997 Feb; 9(1):8-13. PubMed ID: 9090475
[TBL] [Abstract][Full Text] [Related]
20. Listen for the "whispering disease". Learn the subtle signs and symptoms of ovarian cancer.
Martin VR
Nurs Manage; 2000 Apr; 31(4):30-1. PubMed ID: 15127636
[No Abstract] [Full Text] [Related]
[Next] [New Search]
